TY - JOUR
T1 - Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
AU - Pizzuti, Laura
AU - Sergi, Domenico
AU - Sperduti, Isabella
AU - Lauro, Luigi Di
AU - Mazzotta, Marco
AU - Botti, Claudio
AU - Izzo, Fiorentino
AU - Marchetti, Luca
AU - Tomao, Silverio
AU - Marchetti, Paolo
AU - Natoli, Clara
AU - Grassadonia, Antonino
AU - Gamucci, Teresa
AU - Mentuccia, Lucia
AU - Magnolfi, Emanuela
AU - Vaccaro, Angela
AU - Cassano, Alessandra
AU - Rossi, Ernesto
AU - Botticelli, Andrea
AU - Sini, Valentina
AU - Sarobba, Maria G
AU - Fabbri, Maria Agnese
AU - Moscetti, Luca
AU - Astone, Antonio
AU - Michelotti, Andrea
AU - De Angelis, Claudia
AU - Bertolini, Ilaria
AU - Angelini, Francesco
AU - Ciliberto, Gennaro
AU - Maugeri-Saccà, Marcello
AU - Giordano, Antonio
AU - Giordano, Alessandro
AU - Barba, Maddalena
AU - Vici, Patrizia
PY - 2018
Y1 - 2018
N2 - The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.
AB - The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype. One hundred ninety six patients were included (N:196). Body mass index showed no impact on clinical benefit rates in the overall study sample and in the luminal cancer subset (p = 0.12 and p = 0.79, respectively), but did so in the triple negative subgroup, with higher rates in patients with body mass index ≥25 (p = 0.03). In the overall study sample, body mass index did no impact progression free or overall survival (p = 0.33 and p = 0.67, respectively). Conversely, in triple negative patients, progression free survival was significantly longer with body mass index ≥25 (6 vs 14 months, p = 0.04). In this subset, overall survival was more favorable (25 vs 19 months, p = 0.02). The impact of the molecular subtype was confirmed in multivariate models including the length of progression free survival, and number of metastatic sites (p < 0.0001). Further studies are warranted to confirm our findings in more adequately sized, ad hoc, prospective studies.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Combined Chemotherapy Protocols
KW - BMI
KW - Bevacizumab
KW - Bevacizumab-including regimens
KW - Body Mass Index
KW - Breast Neoplasms
KW - Female
KW - HER2-negative metastatic breast cancer
KW - Humans
KW - Kaplan-Meier Estimate
KW - Middle Aged
KW - Paclitaxel
KW - Progression-Free Survival
KW - Receptor, ErbB-2
KW - first-line treatment
KW - triple negative subtype
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Combined Chemotherapy Protocols
KW - BMI
KW - Bevacizumab
KW - Bevacizumab-including regimens
KW - Body Mass Index
KW - Breast Neoplasms
KW - Female
KW - HER2-negative metastatic breast cancer
KW - Humans
KW - Kaplan-Meier Estimate
KW - Middle Aged
KW - Paclitaxel
KW - Progression-Free Survival
KW - Receptor, ErbB-2
KW - first-line treatment
KW - triple negative subtype
UR - http://hdl.handle.net/10807/170713
U2 - 10.1080/15384047.2017.1416938
DO - 10.1080/15384047.2017.1416938
M3 - Article
SN - 1538-4047
VL - 19
SP - 328
EP - 334
JO - CANCER BIOLOGY & THERAPY
JF - CANCER BIOLOGY & THERAPY
ER -